An expert highlights OrigAMI-4, iza-bren plus pembrolizumab, GORTEC IDEAL, and HexAgon-HN ahead of the ESMO Congress 2026.
|Poll|July 27, 2016
Bronchial Mass Discovered in 47-Year-Old Patient
Author(s)Cesar A. Moran, MD
A 47-year-old man presents with a cough and dyspnea. A bronchial mass in found, and a biopsy is performed. What is your diagnosis?
Advertisement
Based on the image shown, what is your diagnosis?
Advertisement
Related to this article
Lisa Carter-Bawa, PhD, APRN, discusses policy barriers, arts-based outreach, AI, and stigma in lung cancer screening.
Experts highlight updated findings from CARTITUDE-2, how to mitigate late toxicities, and other key considerations in the modern multiple myeloma landscape.
Immune checkpoint inhibitors have reshaped treatment for extensive-stage small cell lung cancer, though their role in limited-stage disease remains uncertain.
Cosibelimab is now a preferred, category 2A NCCN option for locally advanced CSCC when curative surgery or radiation is not feasible.
Sofetabart mipitecan produced responses in heavily pretreated high-grade ovarian cancer regardless of folate receptor α expression or prior mirvetuximab soravtansine.
The European Commission approved the pembrolizumab-based regimen for resectable MIBC regardless of cisplatin eligibility based on the KEYNOTE-B15 data.
Training AI on data without good representation of underserved populations may unintentionally widen disparities in lung cancer care.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Gynecologic Oncology Data to Watch at ESMO 2026: De-Escalation and ADCs
2
Cancer Vaccine Combinations Improve 1-Year Survival in Second-Line NSCLC
3
Monitoring Anemia and Optimizing Regimen Selection in Resectable NSCLC
4
The Usefulness of Indocyanine Green in Cytoreductive Ovarian Cancer Surgery
5